Financial health
- Operating income covered interest expense -92.9× in the latest year.
12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $21M | -$9M | 0.0% | -78.0% | — | — | $21M |
| 2024 | $4M | -$21M | 0.0% | -990.8% | — | — | $16M |
| 2023 | $140M | $67M | 0.0% | 51.9% | — | — | $34M |
| 2022 | $5M | -$63M | 0.0% | -1684.5% | — | — | $46M |
| 2021 | $13M | -$33M | 0.0% | -462.2% | -$55M | $34M | $104M |
| 2020 | $0 | -$55M | — | — | -$49M | — | $93M |
| 2019 | $121000 | -$54M | 0.0% | -40430.6% | -$38M | $0 | $42M |
| 2018 | $257000 | -$12M | 0.0% | -11666.5% | -$29M | $15M | $11M |
| 2017 | $257000 | -$25M | 0.0% | -10241.2% | -$25M | $15M | $11M |
| 2016 | — | -$30M | — | — | -$29M | $14M | $36M |
| 2014 | — | -$4M | — | — | -$10M | — | $32M |
| 2013 | — | -$30M | — | — | — | — | $1M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$21M | — | — | — | — | $37M |
| Dec '25 | $19M | $12M | 0.0% | 56.4% | — | — | $21M |
| Sep '25 | $334000 | -$9M | 0.0% | -2516.5% | — | — | $15M |
| Jun '25 | $1M | -$7M | 0.0% | -701.0% | — | — | $11M |
| Mar '25 | $257000 | -$5M | 0.0% | -3350.2% | — | — | $7M |
| Dec '24 | $977000 | -$4M | 0.0% | -824.3% | — | — | $16M |
| Sep '24 | $660000 | -$3M | 0.0% | -1563.6% | — | — | $29M |
| Jun '24 | $736000 | -$14M | 0.0% | -1255.0% | — | — | $26M |
| Mar '24 | $1M | $411000 | 0.0% | -692.5% | — | — | $35M |
| Dec '23 | $6M | -$20M | 0.0% | -397.9% | — | — | $34M |
| Sep '23 | $2M | -$2M | 0.0% | -573.4% | — | — | $44M |
| Jun '23 | $131M | $122M | 0.0% | 88.6% | — | — | $58M |
| Mar '23 | $1M | -$34M | 0.0% | -945.3% | — | $35M | $27M |
| Dec '22 | $2M | -$14M | 0.0% | -1475.1% | — | — | $46M |
| Sep '22 | $2M | -$30M | 0.0% | -1400.2% | — | $34M | $69M |
| Jun '22 | $1M | -$13M | 0.0% | -1643.1% | — | $34M | $119M |
| Mar '22 | $687000 | -$5M | 0.0% | -2873.1% | — | $34M | $95M |
| Dec '21 | $597000 | -$29M | 0.0% | -3734.8% | -$26M | $34M | $104M |
| Sep '21 | $516000 | -$605000 | 0.0% | -3767.6% | -$17M | $29M | $100M |
| Jun '21 | $0 | $2M | — | — | -$12M | $28M | $112M |
How the market has priced SCYX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for SCYNEXIS INC's multi-year trend.
As of FY2025, SCYNEXIS INC reported — of total debt against $21M of cash; operating income covered interest expense -92.9×.
In FY2025, gross margin was —, operating margin -78.0%, and net margin -41.8%.
As of Jun '26, SCYNEXIS INC traded at a price-to-earnings ratio of about 1.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.